[1]萨日,赵红光,关锋,等.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2013,37(1):9-12.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
　SA Ri,ZHAO Hong-guang,GUAN Feng,et al.Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):9-12.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
点击复制

18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第1期
页码:
9-12
栏目:
论著
出版日期:
2013-01-25

文章信息/Info

Title:
Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma
作者:
萨日;  赵红光;  关锋;  林承赫
吉林大学第一医院核医学科, 长春, 130021
Author(s):
SA Ri;  ZHAO Hong-guang;  GUAN Feng;  LIN Cheng-he
Department of Nuclear Medicine, the First Hospital of Jilin University, Changchun 130021, China
关键词:
淋巴瘤; B细胞; 氟脱氧葡萄糖F18; 正电子发射断层显像术; 体层摄影术; X线计算机; 治疗结果; 标准化摄取值
Keywords:
Lymphoma; B-cell; Fluorodeoxyglucose F18; Positron-emission tomography; Tomography; X-ray computed; Treatment outcome; Standardized uptake value
DOI:
10.3760/cma.j.issn.1673-4114.2013.01.003
摘要:
目的 探讨18F-FDG PET/CT在弥漫性大B细胞淋巴瘤(DLBCL)化疗早期及化疗后疗效评价中的临床价值。方法 回顾性分析采用美罗华联合环磷酰胺+多柔比星+长春新碱+泼尼松方案或环磷酰胺+多柔比星+长春新碱+泼尼松方案化疗的34例DLBCL患者的PET/CT结果。所有患者分别在化疗前、化疗6疗程后行PET/CT,比较化疗前后病灶最大标准化摄取值(SUVmax)及病灶最大直径(Dmax);其中12例患者于化疗前、第2疗程结束后、第4疗程结束后行PET/CT,比较3组间的SUVmax与Dmax。对在化疗6疗程后行PET/CT显像已达到完全缓解的8例和部分缓解的10例患者进行临床随访,观察1年无进展生存期(PFS)。结果 ①34例患者化疗前和6疗程化疗后,SUVmax之间和Dmax之间的差异均有统计学意义(t=3.58和2.96,P均<0.05)。②12例患者在化疗前、第2疗程结束后、第4疗程结束后,SUVmax之间和Dmax之间的差异均有统计学意义(F=18.64和4.33,P均<0.05);第2疗程结束后与化疗前相比,病灶Dmax未见显着变化(t=1.05,P>0.05),SUVmax显着降低(t=5.37,P<0.05);第4疗程结束后与化疗前相比,SUVmax之间和Dmax之间的差异均具有统计学意义(t=8.56和3.90,P均<0.05)。③对18例患者进行的随访发现,完全缓解的8例中,PFS>1年者6例,PFS<1年者2例;部分缓解的10例中,PFS>1年者2例,PFS<1年者8例。结论 在DLBCL化疗早期及化疗后的疗效评价上,PET比CT更灵敏,以两种显像方法相结合的PET/CT在淋巴瘤疗效评价上具有较高的临床价值。
Abstract:
Objective To explore the clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B-cell lymphoma(DLBCL).Methods 18F-FDG PET/CT was performed before and after 6 cycles of chemotherapy(R-CHOP or CHOP protocol) in 34 patients.By measuring maximum SUV(SUVmax)and maximum diameter(Dmax),the clinical value of PET and CT were compared in evaluation of curative effect on DLBCL after chemotherapy.Twelve patients underwent PET/CT examination for three times:before treatment,after 2 cycles of chemotherapy and after 4 cycles of chemotherapy.SUVmax and Dmax were compared among three groups.All the 8 patients who have reached complete response and 10 patients who have reached partial response after 6 cycles of chemotherapy were followed-up,and then the one-year progression-free survival (PFS) was observed.Results ①There was significant difference between SUVmax and Dmax before and after 6 cycles of chemotherapy on DLBCL patients(t=3.58 and 2.96,both P<0.05).② There was significant difference among before,after 2 cycles of chemotherapy,after 4 cycles of chemotherapy in SUVmax and Dmax (F=18.64 and F=4.33,both P<0.05).There was significant difference of SUVmax between before and after 2 cycles of chemotherapy (t=5.37,P<0.05),and no difference of Dmax(t=l.05,P>0.05).There was significant difference of both SUVmax and Dmax between before and 4 cycles of chemotherapy (t=8.56 and 3.90,both P<0.05).③Among 8 patients who have reached complete response,6 cases were PFS>1,2 cases were PFS<1.Among 10 patients who have reached partial response,2 cases were PFS>1,8 cases were PFS<1.Conclusions In evaluation curative effect on malignant DLBCL during and after treatment,PET was significantly better than CT.PET/CT as combination of PET with CT had a higher clinical value to evaluate the therapeutic effect of DLBCL.

参考文献/References:

[1] 李洪生,吴湖炳,王全师,等.18F-FDGPET-CT评价弥漫性大B细胞淋巴瘤化疗中期的治疗反应.中华核医学杂志,2011,31(3):145-150.
[2] Meignan M,Itti E,Gallamini A,et al.Interim 18F-fluorodeoxyglu-cose positron emission tomography in diffuse large B-cell lym-phoma:qualitative or quantitative interpretation-where do we stand?.LEUK lymphoma,2009,50(11):1753-1756.
[3] Imataki O,Tamai Y,Yokoe K,et al.The utility of FDG-PET for managing patients with malignant lymphoma:analysis of data from a single cancer center.Intern Med,2009,48(17):1509-1513.
[4] Kasamon YL,Jones RJ,Wahl RL.Integrating PET and PET-CT in-to the risk-adapted therapy of lymphoma.J Nucl Med,2007,48 suppll:SI9-27.
[5] Itti E,Juweid ME,Haioun C,et al.Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma:importance of the reference background.J Nucl Med,2010,51(12):1857-1862.
[6] 阎骅,沈志祥.淋巴瘤循证治疗解读.肿瘤,2008,28(9):733-735.
[7] Petrausch U,Samaras P,Haile SR,et al.Risk-adapted FDG-PET-CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy.Ann Oncol,2010,21(8):1694-1698.
[8] Connors JM.Positron emission tomography in the management of Hodgkin lymphoma.Hematology Am Soc Hematol Educ Program,2011,116(21):317-322.
[9] 李倩,刘建军.18F-FDG PET-CT评价淋巴瘤疗效及预后的价值.国际放射医学核医学杂志,2011,35(4):220-222.

相似文献/References:

[1]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
　Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[2]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
　You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[3]胡娜,吴永港,肖立志,等.18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
　Hu Na,Wu Yonggang,Xiao Lizhi,et al.Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
[4]戴娜,吴翼伟.影像学技术在霍奇金淋巴瘤诊疗中的价值[J].国际放射医学核医学杂志,2014,38(2):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
　Dai Na,Wu Yiwei.The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
[5]杨希,党春江.泌尿系统原发性结外淋巴瘤的临床及影像学表现[J].国际放射医学核医学杂志,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
　YANG Xi,DANG Chun-jiang.The clinical and imaging appearances of primary extranodal lymphoma of the urinary system[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
[6]李艳梅,杨建伟,李鹏,等.单眼虹膜原发非霍奇金淋巴瘤18F-FDGPET/CT显像及疗效评价一例[J].国际放射医学核医学杂志,2013,37(5):326.[doi:10.3760/cma.j.issn.1673-4114.2013.05.017]
[7]王月英,吴红英,李德冠,等.小鼠不同肿瘤模型对放化疗敏感性的研究[J].国际放射医学核医学杂志,2012,36(5):289.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.006]
　WANG Yue-ying,WU Hong-ying,LI De-guan,et al.The radiation sensitivities of different mice tumor model to radiotherapy and chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):289.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.006]
[8]李倩,刘建军.18F-FDG PET-CT评价淋巴瘤疗效及预后的价值[J].国际放射医学核医学杂志,2011,35(4):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
　LI Qian,LIU Jian-jun.The value of 18F-FDG PET-CT in lymphoma therapy evaluation and prognosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
[9]崔玥婵,朱晓琳,张雪君.超声引导下穿刺活检术对颈部淋巴结诊断的现状及进展[J].国际放射医学核医学杂志,2011,35(6):369.[doi:10.3760,cma.j.issn.1673-4114.2011.06.013]
　CUI Yue-chaan,ZHU Xiao-lin,ZHANG Xue-jun.Status and advances of cervical lymph nodes diagnosis by ultrasound-guided core-needle biopsy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):369.[doi:10.3760,cma.j.issn.1673-4114.2011.06.013]
[10]袁航,章斌,邓胜明,等.淋巴瘤细胞株Raji摄取18F-氟脱氧葡萄糖和18F-氟脱氧胸腺嘧啶核苷的体外实验研究[J].国际放射医学核医学杂志,2009,33(6):327.[doi:10.3760/cma.j.issn.1673-4114.2009.06.002]
　YUAN Hang,ZHANG Bin,DENG Sheng-ming,et al.In vitro study of uptaking 18F-fluorodeoxyglucose and 18-fluorodeoxythymidine in human lymphoma Raji cell[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):327.[doi:10.3760/cma.j.issn.1673-4114.2009.06.002]
[11]魏莉,罗荣城.放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展[J].国际放射医学核医学杂志,2006,30(3):153.
　WEI Li,LUO Rong-cheng.Advances in research of radioactive nuclide labeled anti-CD20 monoclonal antibody in B cell lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):153.
[12]秦文琼,高硕.PET/CT与临床预后因素在弥漫大B细胞淋巴瘤疗效评价及预后评估中的应用[J].国际放射医学核医学杂志,2017,41(6):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
　Qin Wenqiong,Gao Shuo.Application of PET/CT and clinical factors in the therapeutic and prognostic evaluation of diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]

备注/Memo

备注/Memo:
收稿日期:2012-09-13。
基金项目:卫生部吴阶平医学基金(项目编号:320.6750.07127)
通讯作者:林承赫,Email:linchh1967@yahoo.com.cn
更新日期/Last Update: 1900-01-01